Dr. Ahmed Abdalla
Claim this profileUniversity of South Alabama Mitchell Cancer Institute
Area of expertise
Cancer
Ahmed Abdalla has run 5 trials for Cancer. Some of their research focus areas include:
Pancreatic Cancer
Ahmed Abdalla has run 4 trials for Pancreatic Cancer. Some of their research focus areas include:
Affiliated Hospitals
University Of South Alabama Mitchell Cancer Institute
Clinical Trials Ahmed Abdalla is currently running
Ipatasertib + Chemotherapy
for Cancer
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has PTEN and AKT genetic changes. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Targeted therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors with PTEN and AKT genetic changes could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression). Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer or stop its growth.
Recruiting
1 award
Phase 2
Chemotherapy Tailored by ctDNA Status
for Colon Cancer
This trial tests if a blood test for cancer DNA can help decide if colon cancer patients need more treatment after surgery. The test looks for cancer DNA in the blood to predict if the cancer might come back and to guide further treatment.
Recruiting
1 award
Phase 2 & 3
More about Ahmed Abdalla
Clinical Trial Related
2 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Ahmed Abdalla has experience with
- Oxaliplatin
- Binimetinib
- Palbociclib
- Paclitaxel
- Sotorasib
- Ipatasertib
Breakdown of trials Ahmed Abdalla has run
Cancer
Pancreatic Cancer
Ovarian Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ahmed Abdalla specialize in?
Ahmed Abdalla focuses on Cancer and Pancreatic Cancer. In particular, much of their work with Cancer has involved KRAS positive patients, or patients who are Stage IV.
Is Ahmed Abdalla currently recruiting for clinical trials?
Yes, Ahmed Abdalla is currently recruiting for 5 clinical trials in Mobile Alabama. If you're interested in participating, you should apply.
Are there any treatments that Ahmed Abdalla has studied deeply?
Yes, Ahmed Abdalla has studied treatments such as Oxaliplatin, Binimetinib, Palbociclib.
What is the best way to schedule an appointment with Ahmed Abdalla?
Apply for one of the trials that Ahmed Abdalla is conducting.
What is the office address of Ahmed Abdalla?
The office of Ahmed Abdalla is located at: University of South Alabama Mitchell Cancer Institute, Mobile, Alabama 36688 United States. This is the address for their practice at the University of South Alabama Mitchell Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.